Five Impressive Metastatic Cancer Treatment Stocks to Own Today May 15, 2023 - Baystreet.ca A significant medical breakthrough is desperately needed in the fight against breast cancer. At the moment, according to the American Cancer Society, more than 3.1 million women in the United States alone have a history of invasive breast cancer. And unfortunately, as it stands, breast cancer deaths are estimated to be more than 43,000 per year – making it the second leading cause of cancer death in women. However, there may be hope on the horizon, with companies such as BriaCell Therapeutics Corp. (NASDAQ: BCTX) (TSX: BCT), Eli Lilly (NYSE: LLY), Puma Biotechnology (NASDAQ: PBYI), Gilead Sciences (NASDAQ: GILD), and ImmunoGen (NASDAQ: IMGN). In addition, according to Research and Markets.com, the global breast cancer drug market could be worth $27.04 billion by 2026. In addition, Global Markets Insights says that number could be closer to $43 billion by 2028, with further advances in breast cancer care. Look at BriaCell Therapeutics (NASDAQ: BCTX) (TSX: BCT), For Example BriaCell Therapeutics, a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announces that the Company has signed a Master Service and Technology Agreement agreement with Prevail InfoWorks, Inc., a Philadelphia, PA based Contract Research Organization (CRO), to provide clinical services and technologies for BriaCell’s upcoming pivotal study in advanced metastatic breast cancer. Services include clinical site coordination, project management, clinical monitoring and pharmacovigilance (safety management) services, and to use InfoWork’s integrated real-time data analytics platform, The Single Interface®, for clinical support and real-time data analysis. Prevail Partners, LLC, an investment fund and affiliate of InfoWorks, has agreed to purchase 463,408 BriaCell common shares at a price of $8.63170 for gross proceeds of $4 million, representing a 20% premium to the volume-weighted average price of the common shares of the Company on the Nasdaq Stock Exchange for the thirty (30) trading days immediately preceding the Effective Date. Subject to exchange approvals and other customary closing conditions, the subscription is expected to close on or about May 19, 2023, with the proceeds used to offset the cash payments otherwise owing to Infoworks under the MSTA. “We have high confidence in Prevail InfoWorks’ ability to coordinate our pivotal clinical trial in advanced breast cancer. They have extensive experience and expertise which should assure rapid accrual and smooth execution of the study. Additionally, fast, reliable data access is essential to successful and timely completion of our upcoming pivotal trial, lowers our clinical risk, and may speed up the FDA approval timeline.” stated Dr. William V. Williams, BriaCell’s President & CEO. “Prevail Partners’ strategic investment in BriaCell’s registration study further highlights the confidence Prevail has in our ability to execute on enrolment targets and subsequent survival data.” Prevail Partners acknowledges and agrees that they are purchasing the Shares pursuant to an exemption from any prospectus, registration or similar requirements under applicable U.S. and Canadian securities laws, and that the offer, sale and delivery of the Shares to Prevail Partners is conditional upon such offer, sale and deliver being exempt from the requirements under applicable securities laws requiring the filing of a prospectus in connection with the distribution of the Shares or upon the issuance of such rulings, orders, consents or approvals as may be required to permit such sale without the requirement of filing a prospectus. The common shares purchased by Prevail Partners are subject to applicable US and Canadian resale restrictions. Other related developments from around the markets include: Eli Lilly announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for Verzenio® (abemaciclib), in combination with endocrine therapy (ET), for the adjuvant treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, early breast cancer (EBC) at a high risk of recurrence. High risk patients eligible for Verzenio can now be identified solely based on nodal status, tumor size, and tumor grade (4+ positive nodes, or 1-3 positive nodes and at least one of the following: tumors that are ≥5 cm or Grade 3).1 This expanded adjuvant indication removes the Ki-67 score requirement for patient selection. Puma Biotechnology, a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2023. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial product. Product revenue, net in the first quarter of 2023 was $46.8 million, compared to product revenue, net of $40.7 million in the first quarter of 2022. “We are pleased to deliver positive net income for the first quarter of 2023. We are additionally pleased to see the recently published results from the TBCRC-041 trial evaluating alisertib in patients with ER-positive HER2-negative metastatic breast cancer that were published in JAMA Oncology in March,” said Alan H. Auerbach, Chairman, Chief Executive Officer and President of Puma. “We look forward to meeting with the U.S. Food and Drug Administration and discussing the next steps for the development of alisertib in both small cell lung cancer and ER-positive HER2-negative metastatic breast cancer during 2023. Additionally, we will continue to focus our efforts toward achieving our goal of increasing awareness of and access to NERLYNX as an option for patients battling HER2-positive breast cancer.” Gilead Sciences announced the U.S. Food and Drug Administration (FDA) approved Trodelvy® (sacituzumab govitecan-hziy) for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. The approval is based on statistically significant and clinically meaningful progression-free survival and overall survival data from the Phase 3 TROPiCS-02 study. ImmunoGen, a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, announced positive top-line data from the Phase 3 confirmatory MIRASOL trial (GOG 3045/ENGOT OV-55) evaluating the safety and efficacy of ELAHERE® (mirvetuximab soravtansine-gynx) compared to chemotherapy in patients with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer who have received one to three prior lines of therapy. Based on these data, the Company plans to submit a Marketing Authorization Application (MAA) in Europe and a supplemental Biologics License Application (sBLA) in the US for the conversion to a regular approval of ELAHERE. Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Winning Media is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement Winning Media has been paid three thousand five hundred dollars for advertising and marketing services for BriaCell Therapeutics Corp. by BriaCell Therapeutics Corp. We own ZERO shares of BriaCell Therapeutics Corp. Please click here for disclaimer. Contact: Ty Hoffer Winning Media281.804.7972Ty@winning.media
Five Impressive Metastatic Cancer Treatment Stocks to Own Today May 15, 2023 - Baystreet.ca A significant medical breakthrough is desperately needed in the fight against breast cancer. At the moment, according to the American Cancer Society, more than 3.1 million women in the United States alone have a history of invasive breast cancer. And unfortunately, as it stands, breast cancer deaths are estimated to be more than 43,000 per year – making it the second leading cause of cancer death in women. However, there may be hope on the horizon, with companies such as BriaCell Therapeutics Corp. (NASDAQ: BCTX) (TSX: BCT), Eli Lilly (NYSE: LLY), Puma Biotechnology (NASDAQ: PBYI), Gilead Sciences (NASDAQ: GILD), and ImmunoGen (NASDAQ: IMGN). In addition, according to Research and Markets.com, the global breast cancer drug market could be worth $27.04 billion by 2026. In addition, Global Markets Insights says that number could be closer to $43 billion by 2028, with further advances in breast cancer care. Look at BriaCell Therapeutics (NASDAQ: BCTX) (TSX: BCT), For Example BriaCell Therapeutics, a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announces that the Company has signed a Master Service and Technology Agreement agreement with Prevail InfoWorks, Inc., a Philadelphia, PA based Contract Research Organization (CRO), to provide clinical services and technologies for BriaCell’s upcoming pivotal study in advanced metastatic breast cancer. Services include clinical site coordination, project management, clinical monitoring and pharmacovigilance (safety management) services, and to use InfoWork’s integrated real-time data analytics platform, The Single Interface®, for clinical support and real-time data analysis. Prevail Partners, LLC, an investment fund and affiliate of InfoWorks, has agreed to purchase 463,408 BriaCell common shares at a price of $8.63170 for gross proceeds of $4 million, representing a 20% premium to the volume-weighted average price of the common shares of the Company on the Nasdaq Stock Exchange for the thirty (30) trading days immediately preceding the Effective Date. Subject to exchange approvals and other customary closing conditions, the subscription is expected to close on or about May 19, 2023, with the proceeds used to offset the cash payments otherwise owing to Infoworks under the MSTA. “We have high confidence in Prevail InfoWorks’ ability to coordinate our pivotal clinical trial in advanced breast cancer. They have extensive experience and expertise which should assure rapid accrual and smooth execution of the study. Additionally, fast, reliable data access is essential to successful and timely completion of our upcoming pivotal trial, lowers our clinical risk, and may speed up the FDA approval timeline.” stated Dr. William V. Williams, BriaCell’s President & CEO. “Prevail Partners’ strategic investment in BriaCell’s registration study further highlights the confidence Prevail has in our ability to execute on enrolment targets and subsequent survival data.” Prevail Partners acknowledges and agrees that they are purchasing the Shares pursuant to an exemption from any prospectus, registration or similar requirements under applicable U.S. and Canadian securities laws, and that the offer, sale and delivery of the Shares to Prevail Partners is conditional upon such offer, sale and deliver being exempt from the requirements under applicable securities laws requiring the filing of a prospectus in connection with the distribution of the Shares or upon the issuance of such rulings, orders, consents or approvals as may be required to permit such sale without the requirement of filing a prospectus. The common shares purchased by Prevail Partners are subject to applicable US and Canadian resale restrictions. Other related developments from around the markets include: Eli Lilly announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for Verzenio® (abemaciclib), in combination with endocrine therapy (ET), for the adjuvant treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, early breast cancer (EBC) at a high risk of recurrence. High risk patients eligible for Verzenio can now be identified solely based on nodal status, tumor size, and tumor grade (4+ positive nodes, or 1-3 positive nodes and at least one of the following: tumors that are ≥5 cm or Grade 3).1 This expanded adjuvant indication removes the Ki-67 score requirement for patient selection. Puma Biotechnology, a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2023. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial product. Product revenue, net in the first quarter of 2023 was $46.8 million, compared to product revenue, net of $40.7 million in the first quarter of 2022. “We are pleased to deliver positive net income for the first quarter of 2023. We are additionally pleased to see the recently published results from the TBCRC-041 trial evaluating alisertib in patients with ER-positive HER2-negative metastatic breast cancer that were published in JAMA Oncology in March,” said Alan H. Auerbach, Chairman, Chief Executive Officer and President of Puma. “We look forward to meeting with the U.S. Food and Drug Administration and discussing the next steps for the development of alisertib in both small cell lung cancer and ER-positive HER2-negative metastatic breast cancer during 2023. Additionally, we will continue to focus our efforts toward achieving our goal of increasing awareness of and access to NERLYNX as an option for patients battling HER2-positive breast cancer.” Gilead Sciences announced the U.S. Food and Drug Administration (FDA) approved Trodelvy® (sacituzumab govitecan-hziy) for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. The approval is based on statistically significant and clinically meaningful progression-free survival and overall survival data from the Phase 3 TROPiCS-02 study. ImmunoGen, a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, announced positive top-line data from the Phase 3 confirmatory MIRASOL trial (GOG 3045/ENGOT OV-55) evaluating the safety and efficacy of ELAHERE® (mirvetuximab soravtansine-gynx) compared to chemotherapy in patients with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer who have received one to three prior lines of therapy. Based on these data, the Company plans to submit a Marketing Authorization Application (MAA) in Europe and a supplemental Biologics License Application (sBLA) in the US for the conversion to a regular approval of ELAHERE. Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Winning Media is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement Winning Media has been paid three thousand five hundred dollars for advertising and marketing services for BriaCell Therapeutics Corp. by BriaCell Therapeutics Corp. We own ZERO shares of BriaCell Therapeutics Corp. Please click here for disclaimer. Contact: Ty Hoffer Winning Media281.804.7972Ty@winning.media